Therefore, while the Thr790Met mutation itself is not directly oncogenic, it is considered pathogenic because it allows tumor cells to continue growing and spreading even in the presence of TKIs, which are the standard of care for EGFR-mutant NSCLC. This evidence concerns the gene EGFR and neoplasm.